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Abstract
Background—Acne reflects hormone imbalance and is a key component of several systemic 
diseases. We hypothesized that diagnosis of acne at teenage might predict subsequent risk of 
hormone-related cancers.
Methods—We followed 99,128 female nurses for 20 years (1989-2009) in the Nurses’ Health 
Study II cohort and used Cox proportional hazards models to estimate the hazard ratios (HRs) of 
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eight specific cancers (breast, thyroid, colorectal, ovarian, cervical, endometrial cancers, 
melanoma and non-Hodgkin’s lymphoma) for women with a history of severe teenage acne.
Results—After thoroughly adjusted for the previously known risk factors of each cancer, we 
found that among women with a history of severe teenage acne, the relative risk increased with 
multivariable-adjusted HR of 1.44 (95% confidence interval [CI], 1.03-2.01) for melanoma. We 
replicated this association in an independent case-control study of 930 cases and 1,026 controls 
(multivariable-adjusted odds ratio, OR, 1.27; 95% CI, 1.03-1.56). We additionally found that the 
individuals with teenage acne were more likely to have moles in both studies (52.7% vs. 50.1%, 
P<0.001 in the cohort study; and 55.2% vs. 45.1%, P=0.004 in the case-control study).
Conclusion—Our findings suggest that a history of teenage acne might be a novel risk factor for 
melanoma independently from the known factors, which supports a need for continued 
investigation of these relationships.
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Introduction
Acne vulgaris, one of the most prevalent skin conditions and the leading diagnosis in 
dermatology, affects more than 85% of teenagers1. It is a follicular phenotype characterized 
by the hyperplasia of the sebaceous glands and seborrhea. Several hormones have been 
linked to acne, including androgens, estrogens, growth hormone, insulin, 
adrenocorticotropic hormone, melanocortins, et al.2. Among them, androgens, the male 
hormones present in both men and women, have long been known to contribute to acne 
flares by over-stimulating the oil glands and altering the development of skin cells that line 
hair follicles in the skin.
Cancer is a systemic disease and a number of major cancers are hormone-related3. 
Compelling evidence has implicated estrogens in the etiology of breast cancer, progesterone 
in the etiology of breast and ovary cancers, and testosterone in the etiology of prostate 
cancer4. Besides, estrogens have been suggested to play a role in many other major cancers, 
including endometrial, ovary, esophageal, colorectal, cervical, thyroid and lung cancers, 
melanoma and non-Hodgkin’s lymphoma5. The hormonal effect of testosterone has been 
suggested in breast 4, ovary6, endometrial7, colorectal8 cancers and melanoma9. Thus, it is 
plausible that acne may be a predictor of cancer risk. It has been suggested that men with 
severe acne had an elevated risk of prostate cancer in the Health Professionals’ Follow-up 
Study10. However, the association between acne and breast cancer risk has been 
inconclusive, with positive, inverse and null association results11-14. To prospectively 
investigate the association between teenage acne and cancer risk in women, we conducted a 
prospective analysis in the Nurses’ Health Study II (NHSII), with 116,430 women followed 
up for over 20 years in the U.S.
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History of severe teenage acne and cancer risk in the NHSII
Study population—The NHSII is a prospective cohort study established in 1989, when 
116,430 female registered nurses aged 25-42 completed an initial questionnaire on their 
medical histories and health-related exposures. Updated information was obtained by mailed 
questionnaires biennially. Details of this cohort have been described previously15. The 
protocol for this study was approved by the Institutional Review Board at Brigham and 
Women’s Hospital and the Harvard School of Public Health. Informed consent was obtained 
from the cohort participants.
Exposure data—Participants reported their history of severe teenage acne on the baseline 
questionnaire in 1989. We collected information on the use of medications for acne 
treatment, including tetracycline and oral isotretinoin (brand name: Accutane) in 1993, and 
the use of antibiotics for acne in 2005. Details on the data of other potential cancer risk 
factors were described in the Supplementary Methods.
Identification of cancer cases—Participants reported cancer diagnoses biennially. With 
their permission, pathological records were obtained and reviewed by physicians to confirm 
diagnosis. Eligible cases consisted of women with incident cancers diagnosed any time after 
the baseline up to the 2009 follow-up cycle. Only pathologically confirmed invasive cases 
were included, except for breast cancer, which included both invasive (n=2,640) and in situ 
(n=663) cases. We included eight specific cancer sites in which the hormonal effects were 
previously implicated and of which there were more than 100 cases. We additionally 
examined non-melanoma skin cancers as a comparison to assess the potential confounders 
of skin cancer risk such as ultraviolet exposure and dermatology clinic visit. Medical records 
were not obtained for self-reported cases of basal cell carcinoma (BCC), but previous 
reports have demonstrated the high validity of self-report of BCC, with more than 90% 
confirmed by histopathology records in the NHS16.
Melanoma case-control study from the MD Anderson Cancer Center
Between April 1994 and April 2008, 930 patients with newly diagnosed, histologically 
confirmed, untreated cutaneous malignant melanoma and 1,026 matched controls were 
consecutively recruited at the MD Anderson Cancer Center. With informed consent, we 
collected information about history of teenage acne as well as demographic and known risk 
factors for melanoma for each patient. We only included U.S. non-Hispanic Europeans in 
this analysis. Details of the study population have previously been described17. The research 
protocol was approved by the Institutional Review Board at the MD Anderson Cancer 
Center.
Plasma Hormone Study
Between 1996 and 1999, a subgroup of NHSII provided plasma samples (n=29,611)18; 19. 
Details of the collection were described in the Supplementary Methods. Women who had 
data for testosterone, sex hormone-binding globulin (SHBG) or dehydroepiandrosterone 
sulfate (DHEAS), and did not report treatments for acne were included. Free testosterone 
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was calculated using the method described by Sodergard et al.20. We selected plasma 
testosterone and DHEAS given their associations with breast cancer risk in the NHSII18; 19. 
Free testosterone is the biologically active form of testosterone and DHEAS is the primary 
circulating form of DHEA.
Statistical Analysis
Participants contributed person-time from the baseline in June 1989 to the end of follow-up 
in June 2009. A total of 99,128 women were included in this study at the baseline after 
excluding those with previous cancers or missing information on the history of severe 
teenage acne. Accumulation of follow-up time ceased at the first report (followed by 
confirmation) of a primary cancer, death, or the end of follow-up, whichever came earlier. 
We adjusted for the previously known risk factors for each cancer in the multivariable Cox 
proportional hazards models and calculate the hazard ratios (HRs) and 95% confidence 
intervals (CIs)21. We calculated false discovery rate (FDR) to adjust for multiple 
comparisons. The P for statistical significance was 0.006 (0.05/8) after the Bonferronni 
correction. We confirmed the proportional hazard assumption by including a time dependent 
exposure (time*acne) in the models (P for proportionality test > 0.05 for all tests). We used 
logistic regression models to calculate the odds ratios (ORs) and 95% CIs of melanoma in 
the melanoma case-control study22. We used the generalized linear models for the analyses 
of hormone levels and calculated the least square means of the steroid hormone levels by 
acne status23. The variables adjusted in the models were presented in the footnotes of each 
table. Missing data were handled by a missing category if any. We conducted a sensitivity 
analysis restricting to the individuals without treatments for acne. All of the statistical 
analyses were carried out using Statistical Analysis System software (version 9.1.3; SAS 
Institute, Cary, NC). All P values were two-sided.
Results
We included 99,128 women in the analysis of severe teenage acne and cancer risk. During 
20 years of follow-up from 1989 to 2009, 3,303 breast cancers, 397 melanomas, 347 thyroid 
cancers, 235 colorectal cancers, 165 non-Hodgkin lymphomas, 118 ovarian cancers, 115 
cervical cancers and 109 endometrial cancers were diagnosed. Additionally, 6,577 BCC 
cases and 475 SCC cases were diagnosed. The distribution of basic characteristics of 
participants with and without history of severe teenage acne was similar (Table 1). There 
was a higher prevalence of prescription medications for acne treatment among those with 
severe teenage acne than those without (24.1 vs. 6.1% for antibiotics; 8.5 vs. 1.2% for 
tetracycline; and 13.0 vs. 1.1 % for oral Accutane). There was no substantial difference 
regarding the characteristics between women with and without information on teenage 
severe acne (Table S1).
In Table 2, we present the HRs and 95% CIs for each specific type of cancers. Among the 
individuals with a history of severe teenage acne, we identified an increased risk of breast 
cancer with crude HR of 1.23 (95% CI, 1.10-1.38; P=0.0005) and multivariable-adjusted HR 
of 1.17 (95% CI, 1.03-1.32; P=0.01), as well as an increased risk of melanoma with crude 
HR of 1.40 (95% CI, 1.02-1.92; P=0.04) and multivariable-adjusted HR of 1.44 (95% CI, 
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1.03-2.01; P=0.03). After the Bonferronni correction, the multivariable-adjusted associations 
became non-significant. The FDR for the multivariable-adjusted associations was 0.08 for 
breast cancer and 0.12 for melanoma. When we further restricted the analysis to individuals 
without acne medication, the risks remained similar to those in the overall analysis (1.18 vs. 
1.17 for breast cancer; and 1.43 vs. 1.44 for melanoma). These associations were essentially 
unchanged in the analysis restricted to Caucasians (multivariable-adjusted HR: 1.16; 95% 
CI, 1.02-1.31 for breast cancer; and 1.49; 95% CI, 1.06-2.08 for melanoma). Previous 
studies have suggested the differential effects of BMI by menopausal status for breast 
cancer24. Among postmenopausal women, the expected effects of BMI on breast cancer risk 
were opposite to that among premenopausal women. Thus, we modified the breast cancer 
models to allow for the differential effects by using a combined group for BMI and 
menopausal status. The results remained essentially unchanged. We further tested the 
interactions between acne history and other known/putative breast cancer risk factors and 
the P for interactions were 0.13-0.86 (Table S2). Besides, we detected the multivariable-
adjusted HRs of 1.13 (95% CI: 0.77-1.65) for thyroid cancer, 1.07 (95% CI: 0.67-1.70) for 
colorectal cancer, 1.40 (95% CI: 0.74-2.65) for endometrial cancer, 1.04 (95% CI: 
0.50-2.07) for cervical cancer, 0.69 (95% CI: 0.31-1.51) for ovarian cancer, and 0.46 (95% 
CI: 0.20-1.05) for non-Hodgkin lymphoma.
We confirmed the association between history of teenage acne and melanoma risk in an 
independent case-control study of 930 melanoma cases and 1,026 controls from the MD 
Anderson Cancer Center. The multivariable-adjusted OR for melanoma risk was 1.27 (95% 
CI, 1.03-1.56, Table 3). The P values for Goodness-of-Fit test were greater than 0.05 for all 
the models. The basic characteristics of participants with and without history of teenage 
acne are presented in Table S3. We additionally found that women with severe teenage acne 
were more likely to have moles compared with those without severe teenage acne in our 
cohort (52.7% vs. 50.1%; P<0.001). This association was replicated among the controls in 
the melanoma case-control study (55.2% vs. 45.1%; P=0.004). The multivariable-adjusted 
HRs for melanoma with and without adjustment for moles were not substantially different in 
our cohort (HR, 1.46, 95% CI, 1.05-2.04 without adjustment for moles v.s. HR, 1.44, 95% 
CI, 1.03-2.01 with adjustment). In the melanoma case-control study, the association between 
acne and melanoma was attenuated after adjusting for moles (OR, 1.42, 95% CI, 1.16-1.73 
without adjustment for moles vs. OR, 1.27, 95% CI, 1.03-1.56 with adjustment). P for 
interaction between acne and moles on melanoma risk was 0.26. These findings were similar 
when we restricted the analysis to the individuals without treatments for acne.
To assess the potential confounders of melanoma risk, such as ultraviolet exposure and 
dermatology clinic visits, we analyzed the risk of non-melanoma skin cancers (including 
first-diagnosed SCC and BCC) by acne status. Individuals with severe teenage acne had a 
decreased risk of SCC (multivariable-adjusted HR, 0.47; 95% CI, 0.29-0.77; P=0.003). This 
association remained similar when we included SCC cases with history of BCC 
(multivariable-adjusted HR, 0.57; 95% CI, 0.37-0.87; P=0.01). No association was found for 
BCC risk (multivariable-adjusted HR, 1.05; 95% CI, 0.96-1.15; P=0.26).
Additionally, we found that women with history of severe teenage acne had higher mid-life 
plasma free testosterone levels compared to those without such a history among a subgroup 
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of our cohort population (0.17 vs. 0.16 ng/dL, p=0.03; Table S4). No difference was found 
for total testosterone or DHEAS.
Discussion
We suggested a history of teenage acne as a risk factor for melanoma by following 99,128 
young women for 20 years in a large well-characterized cohort and validated this association 
in an independent U.S. melanoma case-control study of 930 cases and 1,026 controls. This 
association was independent from previously known melanoma risk factors. We additionally 
confirmed that women with history of severe teenage acne had elevated mid-life free 
testosterone levels, but the magnitude of the difference was small and the clinical 
significance requires further validation.
Acne has been suspected as a result of high levels of circulating androgens. Since 1980s, 
there has been cumulative evidence suggesting that women with acne have elevated 
androgen levels, especially free testosterone levels25; 26. The possible link between 
androgens and melanoma has been speculated about for many years based on the 
phenomenon that men have a higher incidence of melanoma than women9. Experimental 
studies have also supported the role of sex hormones on growth of melanoma27. A recent 
study reported that testosterone had effects on melanoma tumor growth in a dose-dependent 
manner in both in vivo and in vitro assays28. However, previous studies reported 
inconsistent findings on the association between acne and melanoma risk based on small 
case-control study settings (with up to 452 melanoma cases)29-31. Besides, the exact nature 
of the observed androgenic effect remains unclear. One of the mechanisms that we 
hypothesize is that androgens may affect melanoma risk through its influence on telomere 
length. It was reported that the androgen receptor interacts with telomeric proteins and has a 
role in telomere complex stability32. Melanocytes with longer telomere lengths experience a 
delayed entrance into senescence, which may lead to the increased formation of nevi and 
provide these cells with a greater opportunity to acquire additional mutations for the 
malignant transformation33. Long telomeres have been associated with increased number of 
moles and increased risk of melanoma34. Our findings that women with acne history had a 
higher level of circulating testosterones and an increased risk of melanoma support this 
hypothesis.
Of note, women with severe teenage acne did not have an increased risk of BCC or SCC, 
which are strongly associated with ultraviolet exposure, suggesting that the increased risk of 
melanoma was not likely to be confounded by excess ultraviolet exposure for acne 
treatment. However, SCC mainly reflects cumulative lifetime, not early life, exposures, and 
there might still be residual confounding. Besides, women with severe acne may also visit a 
dermatology clinic more often. However, the findings for BCC and SCC argue against 
detection bias. The inverse association between history of acne and SCC risk is worthy of 
further investigation. A previous study reported a highly protective role of endogenous 
estrogen against skin tumorigenesis by diverse agents in the mouse models of SCC35. 
However, there is lack of evidence for the androgenic effect on SCC based on the published 
literatures.
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Additionally, our study suggested that women with a history of severe teenage acne had an 
increased risk of breast cancer. However, this finding became non-significant after adjusting 
for multiple tests. Even though, prospective cohort studies has suggested that high levels of 
pre-diagnostic circulating androgens are associated with increased risk of breast cancer36. A 
prospective nested case-control study of breast cancer within the NHSII cohort has found a 
positive association between plasma testosterone levels and breast cancer risk18. Such an 
association remained essentially unchanged after adjustment for estradiol, suggesting that 
the association with androgens is at least partly independent of estrogen.
Of interest, we most recently found that women with more cutaneous nevi had higher risks 
of breast cancer compared to women with no nevi by following 74,523 female nurses for 24 
years (1986-2010) in the Nurses’ Health Study37. The multivariable-adjusted HR was 1.04 
(95% CI, 0.98-1.10) for 1-5 nevi, 1.15 (95% CI, 1.00-1.31) for 6-14 nevi, and 1.35 (95% CI, 
1.04-1.74) for 15 or more nevi (P for continuous trend=0.003). Women with 6 or more nevi 
had 45.5% higher level of free estradiol and 47.4% higher level of free testosterone 
compared to those with no nevus (P for trend=0.001 for both), which was consistent with 
and supported the present study.
Of note, polycystic ovary syndrome, the most common cause of elevated androgen levels in 
women, has acne as one of its main symptoms. These women have higher infertility rates 
that could explain a higher breast cancer risk due to no or children conceived at a later age. 
However, the parity and age at first birth appear similar comparing women with and without 
acne in our study population, suggesting these factors are unlikely to confound our finding 
on breast cancer.
Another interesting finding was an inverse association between acne and non-Hodgkin 
lymphoma. Previous study found hyper-methylation of the androgen receptor gene in 
follicular non-Hodgkin’s lymphomas, suggesting a suppressed androgenic effect in non-
Hodgkin’s lymphoma38. Given that acne is generally linked to an overexpression of 
androgen, our finding was consistent with the previous report, although the association was 
not strictly statistical significant. Further studies are needed to verify the inverse association 
between androgen and non-Hodgkin’s lymphoma.
Our findings were based on a large prospective cohort study and we were able to thoroughly 
adjust for the previously identified cancer risk factors. We further confirmed teenage acne as 
a surrogate for mid-life androgen levels to predict subsequent cancer risk. Although a single 
plasma hormone measurement provides a reasonable measure of levels over a several-year 
period, most androgenic activity in women originates from the peripheral conversion of 
precursors such as DHEA into androgens within the cells of target tissues, and this activity 
cannot be detected by measuring circulating androgens39. Additionally, women with acne 
have enhanced dermal sensitivity to androgens and breast tissue is embryologically closely 
related to accessory skin structures40, so the presence of acne may reflect end-organ 
response to hormones. One limitation of this study is that we used self-reported information 
on acne and moles, and no standard was specified for acne severity in the questionnaire. 
However, the high education level and interest in health of cohort members allows high 
quality and valid information to be collected on self-administered forms. In addition, a 
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previous study demonstrated that people reporting acne of some severity were likely to have 
seen a physician41 and the majority of studies on mole counts have shown a substantial 
agreement between self-counts and dermatologist counts42. Besides, we did not collect 
information on moderate teenage acne. Hence we were not able to evaluate the dose-
response relationship. We did not collect information on the type of moles or on the number 
of moles on other body parts besides the lower legs, which may lead to a possibility of 
residual confounding. However, examining the limbs only was suggested to be a practical 
and suitable tool for predicting total nevus count based on a previous study43. The self-
reported mole counts in our cohort predict melanoma risk44, and our genome-wide 
association study on self-reported mole count in our cohort confirmed previously identified 
loci in nevogenesis45.
In summary, we identify a history of teenage acne as a novel risk factor for melanoma 
independent of the previously identified risk factors. A history of teenage acne may be an 
early-stage marker of high androgen levels and might have potential importance to help 
identify populations at higher cancer risk. Our findings support a need for continued 
investigation of the relationship between acne and hormone-related cancers.
Supplementary Material
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Acknowledgments
We thank Tricia Li for her statistical and programming support. We thank the participants and staff of the Nurses’ 
Health Study II for their valuable contributions and the following state cancer registries: AL, AZ, AR, CA, CO, CT, 
DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, 
TN, TX, VA, WA, WY. This study was approved by the Connecticut Department of Public Health (DPH) Human 
Investigations Committee. Certain data used in this publication were obtained from the DPH. The authors assume 
full responsibility for analyses and interpretation of these data.
Funding:
The NHSII cohort is supported by the National Institutes of Health grant CA67262 and CA176726. RT Fortner is 
supported in part by the National Institutes of Health T32 grant CA09001.
References
1. James WD. Clinical practice. Acne N Engl J Med. 2005; 352:1463–1472.
2. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. The Medical clinics of North 
America. 2009; 93:1161–1181. [PubMed: 19932324] 
3. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol. 2010; 
28:4038–4044. [PubMed: 20644089] 
4. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000; 21:427–433. 
[PubMed: 10688862] 
5. Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ, Janney CA, Zheng W, 
Potter JD, Sellers TA, et al. Hormone replacement therapy and risk of non-hodgkin lymphoma and 
chronic lymphocytic leukemia. Cancer epidemiology, biomarkers & prevention : a publication of 
the American Association for Cancer Research, cosponsored by the American Society of Preventive 
Oncology. 2002; 11:1466–1471.
6. Li AJ, Karlan BY. Androgens and epithelial ovarian cancer: What’s the connection? Cancer biology 
& therapy. 2008; 7:1712–1716. [PubMed: 19151584] 
Zhang et al. Page 8









7. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones 
in endometrial cancer: review of the evidence and research perspectives. Annals of the New York 
Academy of Sciences. 2001; 943:296–315. [PubMed: 11594550] 
8. Lin JH, Giovannucci E. Sex hormones and colorectal cancer: what have we learned so far? Journal 
of the National Cancer Institute. 2010; 102:1746–1747. [PubMed: 21068431] 
9. Rampen FH, Mulder JH. Malignant melanoma: an androgen-dependent tumour? Lancet. 1980; 
1:562–564. [PubMed: 6102285] 
10. Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA. Acne and risk of prostate cancer. 
International journal of cancer. 2007; 121:2688–2692.
11. Viladiu P, Izquierdo A, de Sanjose S, Bosch FX. A breast cancer case-control study in Girona, 
Spain. Endocrine, familial and lifestyle factors. Eur J Cancer Prev. 1996; 5:329–335. [PubMed: 
8972251] 
12. Baron JA, Weiderpass E, Newcomb PA, Stampfer M, Titus-Ernstoff L, Egan KM, Greenberg ER. 
Metabolic disorders and breast cancer risk (United States). Cancer Causes Control. 2001; 12:875–
880. [PubMed: 11808705] 
13. Lerner MR, Lerner AB. Relationship between carcinoma of the breast and acne. Cancer. 1953; 
6:870–872. [PubMed: 13094635] 
14. Moseson M, Koenig KL, Shore RE, Pasternack BS. The influence of medical conditions associated 
with hormones on the risk of breast cancer. Int J Epidemiol. 1993; 22:1000–1009. [PubMed: 
8144280] 
15. Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. Timing of alcohol use and the 
incidence of premenstrual syndrome and probable premenstrual dysphoric disorder. J Womens 
Health (Larchmt). 2009; 18:1945–1953. [PubMed: 20044856] 
16. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer 
FE. Validation of questionnaire information on risk factors and disease outcomes in a prospective 
cohort study of women. American journal of epidemiology. 1986; 123:894–900. [PubMed: 
3962971] 
17. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi 
AA, Vattathil S, et al. Genome-wide association study identifies novel loci predisposing to 
cutaneous melanoma. Human molecular genetics. 2011; 20:5012–5023. [PubMed: 21926416] 
18. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. 
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal 
women. Journal of the National Cancer Institute. 2006; 98:1406–1415. [PubMed: 17018787] 
19. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, 
Hankinson SE. The association of plasma DHEA and DHEA sulfate with breast cancer risk in 
predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev. 2006; 15:967–971. 
[PubMed: 16702378] 
20. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of 
testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid 
Biochem. 1982; 16:801–810. [PubMed: 7202083] 
21. Christensen E. Multivariate survival analysis using Cox’s regression model. Hepatology. 1987; 
7:1346–1358. [PubMed: 3679094] 
22. Domínguez-Almendros S, B-P N, Gonzalez-Ramirez AR. Logistic regression models. Allergologia 
et immunopathologia. 2011; 39:295–305. [PubMed: 21820234] 
23. Wedderburn RWM, N JA. Generalized Linear Models. Journal of the Royal Statistical Society. 
1972; 135:370–384.
24. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing 
premenopausal versus postmenopausal breast cancer. Proceedings of the Society for Experimental 
Biology and Medicine Society for Experimental Biology and Medicine. 1997; 216:28–43.
25. Schiavone FE, Rietschel RL, Sgoutas D, Harris R. Elevated free testosterone levels in women with 
acne. Archives of dermatology. 1983; 119:799–802. [PubMed: 6225395] 
26. Lucky AW, McGuire J, Rosenfield RL, Lucky PA, Rich BH. Plasma androgens in women with 
acne vulgaris. The Journal of investigative dermatology. 1983; 81:70–74. [PubMed: 6223099] 
Zhang et al. Page 9









27. Simon SR, Ershler WB. Hormonal influences on growth of B16 murine melanoma. Journal of the 
National Cancer Institute. 1985; 74:1085–1088. [PubMed: 3858578] 
28. Allil PA, Visconti MA, Castrucci AM, Isoldi MC. Photoperiod and testosterone modulate growth 
and melanogenesis of s91 murine melanoma. Medicinal chemistry (Shariqah (United Arab 
Emirates)). 2008; 4:100–105. [PubMed: 18336327] 
29. Beral V, Evans S, Shaw H, Milton G. Cutaneous factors related to the risk of malignant melanoma. 
Br J Dermatol. 1983; 109:165–172. [PubMed: 6871096] 
30. Cartwright RA, Hughes BR, Cunliffe WJ. Malignant melanoma, benzoyl peroxide and acne: a pilot 
epidemiological case-control investigation. Br J Dermatol. 1988; 118:239–242. [PubMed: 
2964857] 
31. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III. Reproductive factors and oral 
contraceptive use. Am J Epidemiol. 1995; 141:943–950. [PubMed: 7741124] 
32. Kim SH, Richardson M, Chinnakannu K, Bai VU, Menon M, Barrack ER, Reddy GP. Androgen 
receptor interacts with telomeric proteins in prostate cancer cells. J Biol Chem. 2010; 285:10472–
10476. [PubMed: 20110352] 
33. Bastian BC. The longer your telomeres, the larger your nevus? The American Journal of 
dermatopathology. 2003; 25:83–84. [PubMed: 12544108] 
34. Nan H, Du M, De Vivo I, Manson JE, Liu S, McTiernan A, Curb JD, Lessin LS, Bonner MR, Guo 
Q, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer 
research. 2011; 71:6758–6763. [PubMed: 22028319] 
35. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, Rebessi S, Tanori 
M, Scambia G, Di Majo V, et al. Modulation of basal and squamous cell carcinoma by 
endogenous estrogen in mouse models of skin cancer. Carcinogenesis. 2009; 30:340–347. 
[PubMed: 18952596] 
36. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and 
ovarian cancers: prospective studies. Advances in experimental medicine and biology. 2008; 
630:148–165. [PubMed: 18637490] 
37. Zhang M, Zhang X, Qureshi AA, Eliassen AH, Hankinson SE, Han J. Association between 
cutaneous nevi and breast cancer in the Nurses’ Health Study: a prospective cohort study. PLoS 
medicine. 2014; 11:e1001659. [PubMed: 24915186] 
38. Yang H, Chen CM, Yan P, Huang TH, Shi H, Burger M, Nimmrich I, Maier S, Berlin K, Caldwell 
CW. The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin’s 
lymphomas. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2003; 9:4034–4042. [PubMed: 14519624] 
39. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res. 2009; 11:212. [PubMed: 
19889198] 
40. O’Rahilly, R.; Muller, F. Human Embryology and Teratology. New York: Wiley-Liss; 1992. 
41. Cheng CE, Irwin B, Mauriello D, Liang L, Pappert A, Kimball AB. Self-reported acne severity, 
treatment, and belief patterns across multiple racial and ethnic groups in adolescent students. 
Pediatric dermatology. 2010; 27:446–452. [PubMed: 20796234] 
42. Buettner PG, Garbe C. Agreement between self-assessment of melanocytic nevi by patients and 
dermatologic examination. American journal of epidemiology. 2000; 151:72–77. [PubMed: 
10625176] 
43. Gallus S, Naldi L, Carli P, La Vecchia C. Italian Group for Epidemiologic Research in, D. Nevus 
count on specific anatomic sites as a predictor of total body count: a survey of 3,406 children from 
Italy. American journal of epidemiology. 2007; 166:472–478. [PubMed: 17584758] 
44. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of 
melanoma for whites. J Clin Oncol. 2005; 23:2669–2675. [PubMed: 15837981] 
45. Nan H, Xu M, Zhang J, Zhang M, Kraft P, Qureshi AA, Chen C, Guo Q, Hu FB, Rimm EB, et al. 
Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous 
nevi and melanoma risk. Human molecular genetics. 2011; 20:2673–2679. [PubMed: 21478494] 
Zhang et al. Page 10










We identify a history of teenage acne as a novel risk factor for melanoma independent 
from the previously identified risk factors. Our findings may provide a novel insight into 
the etiology of melanoma. Additionally, a history of acne may be an early-stage marker 
of high androgen levels, which might have potential importance to help identify 
populations at higher risk of hormone-related cancers.
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Table 1
Baseline characteristics of women according to history of severe teenage acne in the NHSII cohort1.
Characteristics Severe teenage acne
No (n=91,202) Yes (n=7,926)
Mean age, years (SD) 34.3(4.7) 34.2(4.6)
Caucasians, % 93.0 93.3
Height, m (SD) 1.6(0.1) 1.6(0.1)
Body mass index, kg/m2 (SD) 24.1(5.0) 24.1(5.0)
Body mass index at age 18, kg/m2 (SD) 21.3(3.4) 21.2(3.2)
Alcohol consumption at 1991, gm/day (SD) 3.1(6.0) 3.0(5.9)
Physical activity, met-h/week (SD) 28.7(70.0) 26.7(64.0)
Multi-vitamin use, % 45.3 48.9
Current smoker, % 13.3 12.2
History of benign breast disease, % 9.8 11.3
Family history of breast cancer, % 5.9 6.2
Current use of oral contraceptive, % 13.3 13.1
Postmenopausal women, % 5.7 6.6
Age at menarche, years (SD) 13.4(1.4) 13.3(1.5)
Parity among parous women, times (SD) 1.4(1.2) 1.3(1.2)
Age at first birth, years (SD) 25.4(4.0) 25.6(4.1)
Red hair color, % 3.9 3.1
Number of severe sunburns at ages 15-20, 5+, % 9.5 10.7
Childhood tendency to severe blistering sunburns, % 6.9 8.2
Presence of moles on lower legs, % 50.1 52.7
Family history of melanoma, % 4.2 5.0
Antibiotics use for acne treatment, % 6.1 24.1
Duration of tetracycline use, 5 years +, % 1.2 8.5
Oral Accutane use, % 1.1 13.0
1
Based on information collected in the 1989 questionnaire unless specified.
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Table 2
History of severe teenage acne and risk of cancers in the NHSII cohort.
Cancers Cases Age-adjusted HR Multivariable-adjusted HR1
Breast cancer 3,303 1.23(1.10-1.38) 1.17(1.03-1.32)2
Melanoma 397 1.40(1.02-1.92) 1.44(1.03-2.01)3
Thyroid cancer 347 1.17(0.81-1.68) 1.13(0.77-1.65)
Colorectal cancer 235 1.15(0.73-1.79) 1.07(0.67-1.70)
Non-Hodgkin lymphoma 165 0.44(0.19-0.98) 0.46(0.20-1.05)
Ovarian Cancer 118 0.73(0.34-1.56) 0.69(0.31-1.51)
Cervical cancer 115 1.09(0.57-2.08) 1.04(0.52-2.07)
Endometrial cancer 109 1.32(0.70-2.45) 1.40(0.74-2.65)
1Adjusted for age, ancestry, body mass index, alcohol consumption, physical activity, multi-vitamin use, smoking status, oral contraceptive use, 
menopausal status and use of hormone replacement, medications for acne treatment including the use of tetracycline, oral Accutane and antibiotics;
2Additionally adjusted for history of benign breast disease, family history of breast cancer, age at first birth and parity, age at menarche, height and 
body mass index at age 18;
3Additionally adjusted for natural hair color, childhood tendency to sunburn, number of sunburns at ages 15-20, family history of melanoma and 
self-reported mole count on lower legs, history of squamous cell carcinoma and basal cell carcinoma.
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Table 3
History of teenage acne and melanoma risk in the melanoma case-control study from the MD Anderson 
Cancer Center.
Melanoma Teenage acne
No (n=1,328) Yes (n=628)
Cases (%), n=930 588 (63.2) 342 (36.8)
Controls (%), n=1,026 740 (72.1) 286 (27.9)
Odds ratio (95% confidence interval)
 Age- and gender-adjusted 1.00 (Ref) 1.50(1.23-1.82)
 Multivariable-adjusted1 1.00 (Ref) 1.42(1.16-1.73)
 Multivariable-adjusted2 1.00 (Ref) 1.27(1.03-1.56)
1Adjusted for hair color, eye color, skin color, freckling when out in the sun, severe blistering sunburns before age 16, and tendency to tan after 
exposure to the sun for 30-40 minutes;
2Additionally adjusted for the presence of moles.
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